Stemline Therapeutics(STML)- NASDAQ
  • Tue, Aug. 23, 9:15 AM
    | Tue, Aug. 23, 9:15 AM
  • Tue, Aug. 23, 8:31 AM
    • The FDA designates Stemline Therapeutics' (NASDAQ:STML) lead product candidate SL-401 a Breakthrough Therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer. It has Orphan Drug status in Europe for the same indication.
    • SL-401 is a recombinant fusion protein composed of certain domains of the diptheria toxin fused to interleukin 3 (IL3). It is called a targeted therapy because the IL3 seeks out IL3 receptors on cancer stem cells (CSCs), the malignant "seeds" of tumors, and tumor bulk of blood cancers. Binding to the receptors delivers the cytotoxin directly to the cancer cells.
    • Breakthrough Therapy status provides for more intensive guidance from the FDA review team, the involvement of more senior agency personnel and a rolling review of the New Drug Application (NDA).
    • Shares are up 26% premarket on light turnover.
    | Tue, Aug. 23, 8:31 AM | 3 Comments
  • Thu, Aug. 4, 8:09 AM
    • Stemline Therapeutics (NASDAQ:STML): Q2 EPS of -$0.52
    • Revenue of $0.24M (+100.0% Y/Y)
    • Press Release
    | Thu, Aug. 4, 8:09 AM | 1 Comment
  • Mon, May 9, 8:08 AM
    • Stemline Therapeutics (NASDAQ:STML): Q1 EPS of -$0.51 beats by $0.08.
    • Revenue of $0.21M (+75.0% Y/Y) beats by $0.06M.
    • Press Release
    | Mon, May 9, 8:08 AM
  • Mon, Mar. 14, 9:56 AM
    • Stemline Therapeutics (STML) Q4 results: Revenues: $0.2M (+100.0%); R&D Expense: $7.9M (+54.9%); SG&A: $2.6M (+30.0%); Operating Loss: ($10.3M) (-47.1%); Net Loss: ($10.2M) (-47.8%); Loss Per Share: ($0.58) (-9.4%).
    • FY2015 results: Revenues: $0.7M (+133.3%); R&D Expense: $29.5M (+39.2%); SG&A: $8.8M (+8.6%); Operating Loss: ($37.6M) (-29.7%); Net Loss: ($37.2M) (-29.2%); Loss Per Share: ($2.15) (+3.6%); Quick Assets: $46M (-14.8%).
    • No guidance given.
    | Mon, Mar. 14, 9:56 AM
  • Mon, Mar. 14, 7:36 AM
    • Stemline Therapeutics (NASDAQ:STML): Q4 EPS of -$0.58 misses by $0.01.
    • Revenue of $0.21M (+75.0% Y/Y) beats by $0.06M.
    • Press Release
    | Mon, Mar. 14, 7:36 AM
  • Nov. 6, 2015, 8:13 AM
    • Stemline Therapeutics (NASDAQ:STML): Q3 EPS of -$0.53 beats by $0.06.
    • Revenue of $0.21M (+200.0% Y/Y) beats by $0.11M.
    | Nov. 6, 2015, 8:13 AM
  • Nov. 2, 2015, 11:30 AM
    • The European Medicines Agency (EMA) designates Stemline Therapeutics' (STML +0.4%) lead product candidate SL-401 an Orphan Drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer.
    • SL-401, also an Orphan Drug for acute myeloid leukemia in the EU and an Orphan Drug for both in the U.S., is a targeted therapy directed to a protein found on cancer stem cells and tumor bulk of blood cancers called interleukin-3 receptor.
    | Nov. 2, 2015, 11:30 AM | 1 Comment
  • Sep. 10, 2015, 12:24 PM
    • The European Medicines Agency designates Stemline Therapeutics' (STML +8.6%) SL-401 an Orphan Drug for the treatment of acute myeloid leukemia (AML). Among the benefits of the status is a 10-year period of market exclusivity for the indication, if approved.
    • SL-401 is a recombinant fusion protein composed of certain domains of the diptheria toxin fused to interleukin 3 (IL3). SL-401 is described as "targeted" because the IL3 seeks out IL3 receptors on cancer stem cells (CSCs), the malignant "seeds" of tumors, and tumor bulk of blood cancers. Binding to the receptors delivers the cytoxin directly to the cancer cells.
    • SL-401 is currently being investigated in three clinical trials across seven indications.
    | Sep. 10, 2015, 12:24 PM
  • Aug. 10, 2015, 4:59 PM
    • Stemline Therapeutics (NASDAQ:STML): Q2 EPS of -$0.58 misses by $0.17.
    • Revenue of $0.12M (+71.4% Y/Y) beats by $0.04M.
    | Aug. 10, 2015, 4:59 PM | 1 Comment
  • May 11, 2015, 8:31 AM
    • Stemline Therapeutics (NASDAQ:STML): Q1 EPS of -$0.46 misses by $0.01.
    • Revenue of $0.12M (+71.4% Y/Y) beats by $0.07M.
    | May 11, 2015, 8:31 AM | 1 Comment
  • Apr. 28, 2015, 1:16 PM
    • Retrophin (RTRX) initiated with a Buy rating and $50 (120% upside) price target by Deutsche Bank.
    • Stemline Therapeutics (STML -0.8%) initiated with Buy rating and $38 (146% upside) price target by H.C. Wainwright.
    • Trillium Therapeutics (TRIL -0.4%) initiated with Outperform rating and $29 (32% upside) price target by Leerink Swann.
    • Juniper Pharmaceuticals (JNP -0.5%) initiated with Buy rating and $15 (102% upside) by Roth Capital.
    • Radius Health (RDUS -2.8%) initiated with a Buy rating and $50 (35% upside) by Maxim Group.
    • DARA Biosciences (DARA +1.1%) initiated with Buy rating and $2 (138% upside) price target by H.C. Wainwright.
    • UniQure (QURE -2.5%) initiated with a Buy rating and $40 (60% upside) by Chardan Capital.
    • NeuroDerm (NDRM -1.7%) initiated with Buy rating and $21 (70% upside) price target by Jefferies.
    • Bluebird bio (BLUE +1.2%) initiated with Buy rating and $190 (42% upside) price target by Maxim Group.
    • Cidara Therapeutics (CDTX -1.9%) initiated with Sell rating and $13 (12% upside) price target by WBB.
    | Apr. 28, 2015, 1:16 PM
  • Mar. 13, 2015, 6:10 PM
    • Stemline Therapeutics (NASDAQ:STML): Q4 EPS of -$0.53 beats by $0.07.
    • Revenue of $0.12M (+71.4% Y/Y)
    • Cash equivalents and investments of $58.6M
    | Mar. 13, 2015, 6:10 PM | 1 Comment
  • Jan. 8, 2015, 12:47 PM
    | Jan. 8, 2015, 12:47 PM | 1 Comment
  • Jan. 8, 2015, 9:15 AM
    | Jan. 8, 2015, 9:15 AM
  • Nov. 12, 2014, 7:35 AM
    • Stemline Therapeutics (NASDAQ:STML): Q3 EPS of -$0.53 beats by $0.05.
    • Cash and cash equivalents of $28.5M
    | Nov. 12, 2014, 7:35 AM
Company Description
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells. It currently developing two clinical stage products: SL-401 and SL-701, as well as a pipeline... More
Sector: Healthcare
Industry: Drug Related Products
Country: United States